The National Institute for Health and Care Excellence (NICE) in England has recommended treatment with Revlimid (lenalidomide) and dexamethasone for multiple myeloma…
News
Cellectar Biosciences’ candidate CLR 131 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma…
The European Commission has approved two combination therapies based on Celgene‘s Revlimid (lenalidomide) and Imnovid (pomalidomide), added to Velcade (…
Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called…
A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide)…
OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in…
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and…
A triple regimen composed of Kyprolis (carfilzomib), thalidomide, and dexamethasone, given before and after high-dose chemotherapy and autologous stem cell transplant, is safe…
Bluebird bio has officially opened a facility in Durham, North Carolina, to make the lentiviral vector needed for its investigational gene and cell treatments, including…
Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an…
